The MetroGel-Vaginal Gel, 0.75 per cent market achieved annual sales of approximately $60.4 million
Glenmark Pharmaceuticals has received final approval by the United States Food & Drug Administration (US FDA) for Metronidazole Vaginal Gel, 0.75 per cent, the generic version of MetroGel-Vaginal Gel, 0.75 per cent, of Bausch Health US.
According to IQVIATM sales data for the 12 month period ending November 2021, the MetroGel-Vaginal Gel, 0.75 per cent market achieved annual sales of approximately $60.4 million.
Glenmark’s current portfolio consists of 173 products authorised for distribution in the US marketplace and 46 ANDA’s pending approval with the US FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
